Patent SG-11201804765U-A (SG)
Title: Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
Inventor: VARGHESE BINDU
IPC: A61K39/00
Filed: 2016-12-21
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 1111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/112775 Al WIPOI PCT (43) International Publication Date 29 June 2017 (29.06.2017) Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). (74) Agents: BRUESS, Steven et al.; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KB, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2016/068030 (22) International Filing Date: 21 December 2016 (21.12.2016) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/270,749 22 December 2015 (22.12.2015) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). (72) Inventors: VARGHESE, Bindu; C/o Regeneron Pharma- ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). THURSTON, Gavin; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). LOWY, Israel; C/o Regener- on Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). BROWNSTEIN, Carrie; C/o [Continued on next page] (54) Title: COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCER (57) : The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically ef- fective amount of an antibody or anti- gen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specific- ally binds to CD20 and CD3. -40- Control - Vehicle r Isotype controls bsAbl RMPI-14 -to bsAb1 + RPMI 4000 E 3500 E 3000 2500 E CD 1500 4 .9 s en 2000 1000 500 0 -500 2 4 6 8 10 12 la 6 18 20 22 24 26 28 30 32 34 36 38 40 Days post implantation -1000 W O 20 17 / 112775 Al Figure 1 WO 2017/112775 V III SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))